medRxiv preprint doi: https://doi.org/10.1101/2023.01.11.23284421; this version posted January 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Depression screening in chronic hemodialysis patients. 1

- 2
- 3

4 Kubanek Alicja^{1¶*}, Przybylak Mateusz², Paul Przemysław¹, Kowalska Anna Sylwia³, Błaszczyk Michał⁴, 5 Macul-Sanewska Aleksandra⁴, Czarnacka Kamila⁵, Bednarski Krzysztof⁵, Kanclerz Katarzyna¹, 6 Szydłowska Aleksandra¹, Świetlik Dariusz⁶, Rutkowski Przemysław⁷, Bidzan Leszek², Renke Marcin¹, 7 Grabowski Jakub^{2&}

- 8
- 9
- 10

11 ¹Department of Occupational, Metabolic and Internal Diseases, Medical University of Gdańsk, Poland

- 12 ²Division of Developmental, Psychotic and Geriatric Psychiatry, Department of Psychiatry, Medical 13 University of Gdańsk, Poland
- 14

18

- 15 ³Individual Specialist Medical Practice Anna Sylwia Kowalska, Gdańsk, Poland
- ⁴Adult Psychiatry Scientific Circle, Division of Developmental, Psychotic and Geriatric Psychiatry, 16 Department of Psychiatry, Medical University of Gdańsk, Poland 17
- 19 ⁵Fresenius Nephrocare Ostróda, Poland
- 20 ⁶Department of Biostatistics and Neural Networks, Medical University of Gdańsk, Poland
- ⁷Department of Internal and Paediatric Nursing, Faculty of Health Sciences, Medical University of 21 22 Gdańsk, Poland.
- 23
- 24
- 25 Corresponding author
- E-mail: akubanek@gumed.edu.pl (AK) 26
- 27

Abstract 28

Purpose 29

30 Depressive disorder is common among hemodialysis (HD) patients and is associated with higher nhafeantaiticip prateit into the state of the served the state of the served served and the served an 31

- 32 insufficient. The aim of the study was to show the prevalence of depression in patients on maintenance
- 33 HD and to discuss the proper diagnostic approach, including dementia screening.

34 Patients and methods

- 35 We conducted a cross-sectional study that included 103 HD patients from one Dialysis Centre in
- 36 Gdańsk (Poland). Cognitive functions were evaluated using Mini–Mental State Examination (MMSE).
- 37 The screening for depression was assessed using Beck Depression Inventory (BDI-II). The diagnosis of
- 38 depressive disorder was confirmed and its severity evaluated by psychiatrists based upon clinical
- 39 assessment and scales. Sociodemographic, laboratory and dialysis data were also collected.

40 Results

- 41 According to BDI-II depressive symptoms were present in 43% of patients while the diagnosis of clinical
- 42 Major Depressive Disorder (MDD) was confirmed by the psychiatrists in 13% of all subjects. In the
- 43 depressive disorder group there was a prevalence of female and patients suffering from diabetes
- 44 mellitus, levels of calcium phosphate index (CaxPi) were higher and Kt/V was lower. The optimal cut-
- 45 off score for diagnosing major depressive disorder using BDI-II was ≥ 20 points. Cognitive impairment
- on the level of major neurocognitive disorder (dementia) was found in 18 % of the study group.

47 Conclusions

- 48 The prevalence of depression assessed using self- or clinician-administered questionnaires was higher
- than reported by clinical interview performed by the psychiatrist. Higher scores of CaxPi and lower
- 50 Kt/V in depressive patients may suggest worse compliance in this group. The psychiatrist's examination
- as a part of care at the Dialysis Centre could improve diagnosis of depression and its treatment with
- 52 the goal to improve quality of life and lower the mortality rate in this population.
- 53
- 54

55

56 Introduction

57 Unipolar depression is highly prevalent in adult population worldwide with twelve month 58 prevalence of major depressive disorder (MDD) being around five percent [1]. The lifetime prevalence 59 of MDD and persistent depressive disorder (dysthymia) is approximately 18 percent in developed 60 countries [2,3]. Among outpatients with general medical disorders prevalence of depressive 61 syndromes is even higher than in general population [4]. MDD and its life prevalence is more common 62 in younger population [3], women [5] as well as in divorced and widowed adults [3].

Kidney diseases have significant impact on global health. The number of patients with all-stage
chronic kidney disease (CKD) reached almost 700 million in 2017. The prevalence of patients requiring
dialysis is over 3 million in the world's population [6]. The incidence of end-stage renal disease (ESRD)

is increasing in recent years and in-centre hemodialysis (HD) remains the most common form of renal
replacement therapy (RRT) [7]. The median country-specific use of HD is depending mostly on its
variable availability [8]. The number of people receiving RRT is expected to keep rising in next decade
and reach over 5.4 million in 2030 driven by population ageing and increasing prevalence of diabetes
and hypertension [9].

71 Depression is the most common psychiatric disorder among patients with ESRD treated with 72 maintenance hemodialysis (MHD) [10]. Its prevalence is reaching approximately 20 to 40% and is 73 statistically higher while using self- or clinician administered questionaries compared to the clinical 74 interview [11]. Estimating the prevalence of depression in MHD population is difficult due to variety of 75 definitions and assessment techniques [12] as well as the overlapping somatic symptoms. The strong 76 association between depression and all-cause mortality risk in patients receiving MHD is observed [13, 77 14]. Affective and cognitive symptoms of depression may be a better predictor of long-term mortality 78 than somatic symptoms in patients undergoing HD [15]. Depressive symptoms are also independently 79 associated with dialysis nonadherence, health resource utilization [16] and decreased quality of life 80 (QoL) [17]. Performing routine screening for depression has been proposed by Centres for Medicare and Medicaid Services in United States [18] and was suggested in Kidney Disease Outcomes Quality 81 82 Initiative (KDOQI) guidelines for cardiovascular disease in dialysis patients [19]. Nevertheless 83 depression screening and treatment in dialysis population remains insufficient [20].

84 The research evaluating diagnostic accuracy of screening tools for depression in patients with 85 kidney failure is limited and future research is still needed [21]. The best studied assessment tool so far is Beck Depression Inventory II (BDI-II) [22]. Few studies compared the effectiveness of BDI-II with 86 87 clinical interview in diagnosing MDD [23, 24, 25, 26], also in the elderly MHD population [27]. According 88 to the studies BDI-II is not a valid tool compared to clinical interview if the traditional cut-off score of 89 10 is used and the threshold of 15 points and above is suggested to be more accurate in hemodialysis 90 population [23,24,25]. On-dialysis assessments using BDI-II can be a convenient screening procedure 91 that could promote regular evaluation compared with the off-dialysis tests [23].

Among screening tools used to evaluate the prevalence of depression are the Cognitive Depression Index (CDI) used to eliminate the somatic elements of the BDI-II form [23, 26], the Center for Epidemiological Studies Depression Scale (CES-D) [28], the Hospital Anxiety and Depression Scale-Depressive Subscale (HADS-D) [29], Geriatric Depression Scale 15 (GDS-15) [27], Initial Depression Inventory- Maintenance Hemodialysis (ID-MHD) [30] and other.

97 Approximately thirty percent of hemodialysis patients suffer from dementia [31, 32] and its 98 prevalence is even higher among older patients and those with severe somatic conditions [33].

99 Therefore the limitations of self- administered rating scales should be considered as well as excluding100 cognitive impairment before stating the diagnosis of depression [34].

101 The effects of depression diagnostics in hemodialysis population are unsatisfactory. The aim of the

102 study was to search the most effective method of diagnosing depressive symptoms in hemodialysis

103 patients leading to more efficient treatment.

104

105 Methodology

The primary aim of the study was to evaluate the prevalence of depression using BDI-II as a screening tool performed by the medical staff in Dialysis Centre compared with the gold standard clinical interview performed by a psychiatrist. We also performed screening for dementia using Mini-Mental State Examination (MMSE) but did not exclude the patients that met the criteria of cognitive impairment in MMSE from the follow-up, due to the possibility of pseudo-dementia in the course of MDD.

112

Study population

Adult ESRD patients of the Hemodialysis Centre in Gdansk (Poland) were involved into the study 114 and were observed for 18 months. We recruited patients that were over 18 years old and had been 115 116 receiving HD for at least 3 months. We excluded patients with major psychiatric disorders other than 117 depression. The study group received the high-flux hemodialysis or hemodiafiltration three times 118 weekly. Cognitive functions were assessed clinically by the psychiatrists, as well as using the MMSE 119 [35]. MMSE was evaluated subsequently after at least 6 months and in the end of observation. Patients that met the criteria of moderate or severe dementia were excluded from the depression evaluation. 120 121 The demographic, clinical and laboratory data of the study group was obtained. The severity of comorbidities was scored with the use of Charlson comorbidity index (CCI) [36, 37]. 122

123

124 Study design

The study was performed in one Dialysis Centre and received ethics approval by the Independent Bioethics Committee for Scientific Research of the Medical University of Gdansk. All the tests and interviews were performed during the dialysis sessions, at least one hour after the initiation and one hour before the termination of the procedure.

Before performing the depression screening we administered the MMSE questionnaires to all the patients in order to evaluate the cognitive function [35].

The screening tool used to measure the symptoms of depression was the Beck Depression Inventory II [22]. The screening was followed by the clinical assessment performed by the psychiatrist. All the clinicians were experienced in examining patients with chronic illnesses and were blind to the results of BDI-II.

One of the tools used by the psychiatrists was The Mini International Neuropsychiatry Interview (MINI) [38] determining if the patient fulfills the criteria of MDD according to Diagnostic and Statistical Manual of Mental Disorders V (DSM-V). The Montgomery-Asberg Depression Rating Scale (MADRS) was used by the psychiatrists to define the severity of depressive symptoms [39]. It was used previously in few studies in MHD population [40, 41]. It requires a lot of time and involvement, but is a gold standard in monitoring depressive disorders that accurately reflects improvement during the treatment.

142

143 Statistical analysis

All statistical calculations were performed using the Statistica, the StatSoft Inc. statistical package 144 145 (2014) (data analysis software system) version 12.0. (www.statsoft.com) and the Microsoft Excel spreadsheet, developed by Microsoft Inc. Quantitative variables were characterized by the arithmetic 146 147 mean, standard deviation (SD), median, minimum and maximum value (range) and 95% CI (confidence 148 interval). The variables of the qualitative type were presented in terms of counts and percentages 149 (percentage). The Shapiro-Wilk W test was used to check whether the quantitative variable came from 150 a normally distributed population. The Leven (Brown-Forsythe) test was used to test the hypothesis of 151 equal variances. The significance of differences between the two groups (model of unrelated variables) 152 was tested by means of tests of significance of differences: Student's t-test (or in the case of lack of 153 homogeneity of variance, Welch's test) or the Mann-Whitney U test (in case of failure to meet the 154 conditions of applicability of the Student's t-test or for variables measured on the scale ordinal). The significance of differences between more than two groups was checked with the F (ANOVA) or Kruskal-155 156 Wallis test (in case of failure to meet the applicability conditions of ANOVA). When statistically significant differences were obtained between the groups, post hoc tests were used (Tukey's test for 157 158 F, Dunn's test for Kruskal-Wallis). In the case of the model of two related variables, the Student's t-test 159 or the Wilcoxon-pair-order test was used (in the case of failure to meet the applicability conditions of 160 the Student's t-test or for variables measured on an ordinal scale). The significance of differences 161 between more than two in the model of related variables was checked by analysis of variance with

162 repeated measures or Friedman's test (in case of not meeting the applicability conditions of ANOVA 163 with repeated measures or for variables measured on an ordinal scale). Chi-square tests of 164 independence were used for qualitative variables (using the Yates correction for cell counts below 10, 165 respectively, checking Cochran conditions, Fisher's exact test). In order to establish a relationship, strength and direction between the variables, a correlation analysis was used to calculate the Pearson 166 and /or Spearman correlation coefficients. In all calculations, p = 0.05 was adopted as the level of 167 168 significance. The value under the Beck ROC curve is 1.00. The cut-off point determines the tangent method and the 169

- 170 index is> = 20. Sensitivity 1.0, Specificity 1.0, PPV 1.0, NPV 1.0.
- 171

172 **Results**

173 The total number of 103 patients agreed to participate in the study. During the observation 13 patients died, 3 underwent kidney transplantation and 9 patients resigned during the follow-up. In the 174 175 study group there was a prevalence of male (66%), the mean age of the participants was 67 years. The 176 most common known primary cause of ESRD was diabetes mellitus (29%) and glomerulonephritis 177 (21%) followed by hypertension and ischemia (13%). Forty three percent of participants were 178 suffering from diabetes mellitus. The dominant vascular access was the permanent catheter (64%), 179 arteriovenous fistula was used in 35% of cases, the temporary catheter in 1%. The mean CCI score was 180 above 6 points, which is interpreted as the severe comorbidity. Mild comorbidity was found in 5%, moderate in 14% and severe in 80% of the patients. The more precise sociodemographic and clinical 181 182 data are presented in Table 1.

183 Table 1. Sociodemographic and clinical data

Parameter	<i>n</i> =103		
Gender			
Men, <i>n</i> (%)	69 (67.0%)		
Women <i>, n</i> (%)	34 (33.0%)		
Mean age, yr (SD)	67,3 (13,5)		
Transplantation during observation, n	3 (2.9%)		
Death during observation, n	13 (12.6%)		
Dialysis vintage, yr (SD)	3,9 (3,6)		
Vascular access			
arteriovenous fistula	36 (34,9%)		
permanent catheter	66 (64%)		
temporary catheter	1 (0,97%)		
Primary etiology of CKD, n (%)			
Diabetes mellitus	30 (29,1%)		
GN	22 (21,3%)		

Hypertension and ischemia	14 (13,5%)
ADPKD	7 (6,8%)
Other	17 (16,5%)
Unknown	13 (12,6%)
Diabetes, n	57 (55,3%)
Charlson Comorbidity Index, medium (SD)	6,7 (2,6)

184 SD-standard deviation, CKD- chronic kidney disease, GN- glomerulonephritis, ADPKD- Autosomal

Dominant Polycystic Kidney Disease 185

186

187

The percentage of patients that met the criteria of dementia according to MMSE was 18. Mild 188 cognitive impairment (MCI) was found in 17% of the patients, mild dementia in 14% and moderate in 189 190 4% (Table 2). Thirty six percent of the patients that were later diagnosed with major depressive disorder met the criteria of MCI or mild dementia. Patients with moderate and severe dementia were 191 192 excluded from depression evaluation.

193 Table 2. Dementia screening in MMSE

<i>n</i> =82			
Normal range	53 (64,6%)		
Mild cognitive impairment	14 (17,1%)		
Mild dementia	12 (14,6%)		
Moderate dementia	3 (3,7%)		
Data of the three groups	I- with depressive	II- with major	III- non-depressive
	symptoms according	depressive disorder	group
	to BDI II and non-	diagnosed by	
	depressive according	psychiatrist	
	to clinical interview		
	performed by		
	psychiatrist		
n=78	<i>n</i> =21	n=13	n=44
Normal range	10 (58,8%)	7 (63.6%)	46 (65,7%)
Mild cognitive impairment	4 (23,5%)	2 (18,2%)	12 (17,1%)
Mild dementia	2 (11,8%)	2 (18,2%)	10 (14,3%)
Moderate dementia	1 (5,9%)	0 (0,0%)	2 (2,9%)

194 **MMSE-** Mini-Mental State Examination

195

196

197 In the study group 34 patients (43.6%) were diagnosed with depressive symptoms according to 198 BDI-II. The mean BDI-II score in the study group was 12 points (SD 8,1). The percentage of patients that 199 met criteria of depressive symptoms according to the MADRS alone with the cut-off of 10 or more 200 points was 43.6%. Mild depression was diagnosed in 26,9% of patients, moderate in 10,3% and severe 201 in 6.4%. The criteria of major depressive disorder which took into account clinical evaluation, MINI-202 scale, MADRS cut-off points, CGI-S and MMSE results were met by 13 participants (16,7%). In the MDD 203 group the mean BDI-II score was 26 points compared with non-MDD group with mean 9 points. All the 204 patients that were diagnosed with moderate or severe depressive symptoms using BDI-II were later 205 diagnosed with MDD by the psychiatrist. The optimal cut-off point for BDI-II in diagnosing MDD was 206 equal or greater than 20 points (Table 3).

207 Table 3. The optimal BDI-II cut-off point for diagnosing major depressive disorder

BDI-II	Depression	No depression	P-value
	<i>n</i> =13	<i>n</i> =65	
			<0.0001
mean(SD)	26,5 (4,5)	9,2 (5,1)	
range	20,0-34,0	0,0-19,0	
median	26,0	9,0	

208 BDI-II- Beck Depression Inventory II, SD- standard deviation

209

210

We compared the group of participants that met no criteria of depression (neither in BDI-II, nor in 211 212 clinical interview) with the group having depressive symptoms according to BDI-II which was not 213 confirmed in the clinical interview and the group of patients that met both the criteria of BDI-II and 214 the gold standard clinical interview (Table 4). Out of 44 patients diagnosed with depressive symptoms 215 only one person was being treated for depression before the study, including none in the group with MDD. 216 217 No statistically significant differences were found in the three groups considering comorbidity. 218 However in the MDD group all the patients met the criteria of severe comorbidity while in the other

two groups the percentage was around 75%.

220 Table 4. Data of the three groups:

221 I-with depressive symptoms according to BDI II and non-depressive according to clinical interview

222 performed by psychiatrist, II-with major depressive disorder diagnosed by psychiatrist, III- non-

223 depressive group

224

Parameter	Group I	Group II	Group III	Together	P-value
	n=21	n=13	n=44	n=78	

It is made available under a	CC-BY 4.0 International lic	ense.

Sex	female	14 (66.7%)	5 (38.5%)	33 (75.0%)	52 (66.7%)	0.0491 ¹
	male	7 (33.3%)	8 (61.5%)	11 (25.0%)	26 (33.3%)	
Age	mean (SD)	69.4 (15.4)	67.2 (16.2) 36.0-	66.0 (10.9)	67.1 (13.1)	0.4472 ³
	range	36.0-93.0	86.0	26.0-87.0	26.0-93.0	
	median	67.0	72.0	68.0	69.0	
	95%CI	[62.4;76.4]	[57.4;77.0]	[62.6;69.3]	[64.2;70.1]	
BMI	mean (SD)	27.0 (4.4)	25.3 (4.8)	27.2 (5.3)	26.8	0.4753 ²
	range	17,5-37.2	18.6-34.3	17.5-40.8	17.5-40.8	
	median	27.0	25.4 [22.4;28.2]	26.9	26.9	
	95%CI	[25,0;29.0]		[25.6;28.8]	[25.7;28.0]	
Dry weight	mean (SD)	72,6 (13.6)	71.0 (12.9) 52,0-	78,7 (16,3)	76,8 (15,2)	0.3791 ³
	range	46,0-104,5	92,0	51,5-125,0	46,0-125,0	
	median	75.0	73,5 [63,3;78,8]	75,8	74,8	
	95%CI	[70,0;82,4]		[73,8;83,7]	[73,3;80,2]	
Diabetes		11 (52,4%)	9 (69,2%)	14 (31,8%)	34 (43,6%)	0.0366 ¹
Charlson Index	1-2	2 (9.5%)	0 (0.0%)	2 (4.5%)	4 (5.1%)	0.1597 ³
	3-4	3 (14.3%)	0 (0.0%)	8 (18.2%)	11 (14.1%)	
	>=5	16(76.2%)	13 (100.0%)	34 (77.3%)	63 (80.8%)	
Hb	mean (SD)	10,9 (1,2)	10,8 (1,4)	10,8 (1,3)	10,8 (1,2)	0.9204 ²
g/dl	range	9,3-13,2	9,0-13,3	8,4-13,8	8,4-13,8	0.5204
g/ui	median	10,8	10,7	10,7	10,7	
	95%CI	[10,4;11,4]	[9,9;11,7]	[10,7]	[10,5;11,1]	
К						0.7282 ³
	mean (SD)	4,9 (0,6)	4,9 (0,8)	5,0 (0,6)	5,0 (0,6)	0.7282
mmol/l	range	3,8-6,0	3,4-5,9	4,0-6,4	3,4-6,4	
	median	4,7	5,2 [4,3;5,4]	5,0	5,0	
<u> </u>	95%CI	[4,6;5,2]		[4,9;5,2]	[4,8;5,1]	0.00002
Ca x Pi	mean (SD)	44,8 (11,4)	54,9 (14,5)	44,6 (12,9)	46,3 (13,1)	0.0690 ³
	range	28,0-62,4	29,0-71,0	18,0-68,0	18,0-71,0	
	median	43,0	58,5	44,5	45,0	
	95%Cl	[39,6;50,0]	[45,7;64,1]	[40,7;48,6]	[43,3;49,3]	
Ca x Pi	mean (SD)	44,781 (11,441)	54,917 (14,526)	-	-	0,0473
	range	28,000-62,400	29,000-71,000			
	median	43,000	58,500			
	95%CI	[39,573;49,989]	[45,688;64,146]			
Kt/V	mean (SD)	1,6 (0,3)	1,5 (0,7)	1,5 (0,3)	1,5 (0,4)	0.0867 ³
	range	1,2-2,3	0,9-3,1	0,9-2,2	0,9-3,1	
	median	1,6	1,2	1,6	1,5	
	95%CI	[1,5;1,7]	[1,0;2,0]	[1,4;1,6]	[1,5;1,6]	
Kt/V	mean (SD)	1,600 (0,303)	1,459 (0,657)	-	-	0,0477
	range	1,200-2,250	0,890-3,130			
	median	1,590	1,240			
	95%CI	[1,458;1,742]	[0,954;1,964]			
Albumin	mean (SD)	39,5 (4,3)	38,2 (4,1)	40,7 (3,4)	39,9 (3,8)	0.1813 ²
g/l	range	29,0-46,0	31,0-44,0	33,0-46,0	29,0-46,0	
· ·	median	40,0	38,5	41,0	40,0	
	95%CI	[37,4;41,5]	[35,6;40,8]	[39,6;41,7]	[39,0;40,8]	
РТН	mean (SD)	711,8 (609,3)	702,4 (569,8)	801,9 (710,8)	760,0(654,4)	0.9875 ³
pg/ml	range	94,0-2517,0	262,0-2104,0	3,0-3000,0	3,0-3000,0	
	median	546,0	438,0	529,0	529,0	
	95%CI	[418,1;1005,5]	[319,6;1085,2]	[564,9;1038,9]	[600,4;919,6]	

PSP r	mean (SD)	63,3 (17,5)	52,8 (21,3)	66,1 (21,5)	63,1 (20,8)	0.1436 ³
	range	25,0-91,0	25,0-90,0	30,0-100,0	25,0-100,0	
	median	63,0	45,0	60,5	60,0	
	95%CI	[54,9;71,8]	[39,2;66,3]	[59,2;73,0]	[58,2;68,0]	
Antidepressant	yes	1 (5,3%)	4 (33,3%)	3 (7,5%)	8 (11,3%)	0.89261
treatment	no indications	10 (52,6%)	5 (41,7%)	29 (72,5%)	44 (62,0%)	
	refusal	7 (36,8%)	3 (25,0%)	7 (17,5%)	17 (23,9%)	
	during treatment	1 (5,3%)	0 (0,0%)	1 (2,5%)	2 (2,8%)	
Antipsychotic treatment		1 (4,8%)	2 (16,7%)	0 (0,0%)	3 (4,1%)	0.03801
before the						
study						

¹Chi-square²ANOVA,³Kruskal-Wallis;⁴post-hoc, SD- standard deviation, CI- confidence interval

BMI- body mass index, Hb- hemoglobin, K- potassium, Ca x Pi- calcium phosphate index, Kt/V parameter used to quantify hemodialysis treatment adequacy (K-dialyzer clearance of urea, t- dialysis
 time, V-volume of distribution of urea), PTH- parathyroid hormone, PSP- personal and social
 performance scale

In the MDD group the number of females and patients with diabetes mellitus was statistically higher. There were also statistically significant differences found between the groups according to calcium phosphate index (Ca x Pi) and Kt/V (K – dialyzer clearance of urea t– dialysis time V– volume of distribution of urea). In the MDD group Ca x Pi score was higher and Kt/V was statistically lower compared with the non-MDD groups. We found no statistically significant differences in albumin level, body mass index (BMI) and dry weight.

236

237

Discussion

In the study group the mean age of the participants was over 65 years with the high prevalence of comorbidities. The prevalence of female, patients with diabetes and severe comorbidity was higher in the depressive group. The number of patients diagnosed with depressive symptoms using BDI-II was nearly three times higher compared with the gold standard psychiatrist examination. The optimal cutoff point for BDI-II in diagnosing major depressive disorder was higher that the one for the general population. The percentage of patients that met the criteria of mild cognitive impairment and dementia was significant.

The aging of HD population and the increase in number of chronic diseases is observed in recent years [7, 42]. Women predominated among patients with depression, which is consistent with the

trend observed in general population. The mortality of the studied population in noteworthy. The mortality rate among hemodialysis population is high and its risk may be increased in the elderly population, especially in the first months after initiating dialysis [43]. Diabetes mellitus and high comorbidity are suggested among risk factors for the development of depression in HD population [44].

Dementia can distort diagnosis of depression and influence the results of its treatment. However the suggestion of cognitive impairment in MMSE doesn't exclude the depressive pseudo-dementia and doesn't take into consideration conditions of examination. Dialysis patients with greater burden of depressive symptoms may perform worse in tests of cognition related to processing speed and executive function [45]. Therefore patients which met the criteria of mild cognitive impairment and mild dementia in MMSE were not excluded and followed to depression screening, the number of those later diagnosed with MDD by the psychiatrist was significant.

260 The high prevalence of patients reporting depressive symptoms in BDI-II may suggest the 261 limitations of self-administered questionnaires in this population due to numerous comorbidities and 262 the dialysis procedure itself. On the other hand patients may report symptoms more sincerely in self-263 questionnaire than during the psychiatrist's examination. Even though BDI-II may over diagnose 264 depression, the regular screening using self-administered questionnaires is advisable and easy to 265 perform. Especially patients reporting moderate and severe depressive symptoms should follow to 266 further evaluation. The percentage of patients that met the criteria of depressive symptoms according 267 to MADRS alone was much higher than the one narrowed to moderate or severe depression or the 268 one taking into account CGI, MMSE and clinical diagnosis. It can suggest that the majority of 269 hemodialysis patients presenting the depressive symptoms in the clinical scales do not have MDD. 270 From this point of view starting the depression treatment can be ineffective or even harmful. It may 271 also suggest that they have mild symptoms and require psychotherapy, they can be suffering from 272 dementia and require different approach or they have other mental disorders. The lack of precise 273 diagnostics in the studies on the efficacy of antidepressant treatment in this group of patients may be 274 the reason for the ineffectiveness of therapy giving the false negative results. Therefore psychiatrists 275 examination remains the gold standard in diagnosing depression in HD population. In our study the 276 optimal cut-off point for BDI-II in diagnosing major depressive disorder was higher that the one stated 277 for the general population and higher than the scores suggested in previous studies [23, 25]. As 278 mentioned before, HD patients suffer from numerous comorbidities causing somatic symptoms which 279 may be reported in the BDI-II.

280

We found statistically significant differences between the three groups according the CaxPi. In

the real depression group the index score was highest which can indicate worse adherence to the dietary recommendations. Phosphate retention is a potentially modifiable risk factor for cardiovascular mortality in patients with CKD [46,47]. There were no significant differences in albumin and hemoglobin levels; other parameters suggested to be associated with future cardiovascular events [47]. In the depression group Kt/V was statistically lower which may suggest worse compliance and affect the adequacy of dialysis treatment. Therefore the proper diagnosis and treatment of depression might have a positive impact on compliance and improve the dialysis parameters.

The were no statistically significant differences in body mass index (BMI) and dry weight between the groups. Nevertheless those parameters were higher in the non-MDD group which might suggest the loss of appetite in the depressive group. The higher body mass index has been associated with the better survival in some studies [48], however its limitations as a single parameter should be considered.

293

294 Limitations and strengths

The limitations of our research is small number of patients, cross-sectional design of the study and Covid-19 pandemic conditions. The strengths are the restrictive criteria of the study and the assessment using different scales and the gold standard clinical interview in accordance with the DSM-V criteria. The study examination schedule was mimicking the real life conditions of screening for depression in Dialysis Centre.

300

301 Future Outlook

The possible directions of future research may involve correlation between depression and cognitive impairment in hemodialysis patients. The proper screening algorithm might improve the treatment of depression and have an impact on patient QoL and compliance.

305

306 **Conclusions**

Taking into consideration the high prevalence of depressive disorder and dementia there is a need of regular screening in HD patients. The prevalence of depressive symptoms was higher while using self-questionnaires compared with clinical interview. None of the patients with MDD was receiving antidepressant treatment before the study. In the depression group we found predominance of female, patients with diabetes and severe comorbidity. BDI-II may be the useful screening tool for the dialysis team however the psychiatrist examination remains the gold standard in diagnosing

- depression. In the hemodialysis population the BDI-II cut off point for diagnosing depressive symptoms
- may be higher compared with the general population. The regular psychiatrist examination as a routine
- 315 approach in Dialysis Centre might improve patients quality of life and compliance.